Com­pany in In­dia launches drug for COVID-19 pa­tients

Fiji Sun - - WORLD NEWS -

New Delhi: In­dian phar­ma­ceu­ti­cal com­pany Ci­pla has launched remde­sivir lyophilize­d pow­der for 100mg in­jec­tion to treat se­vere COVID-19 pa­tients in the do­mes­tic mar­ket, a com­pany state­ment said. Remde­sivir is a broad-spec­trum an­tivi­ral med­i­ca­tion de­vel­oped by the U.S. based bio­phar­ma­ceu­ti­cal com­pany Gilead Sciences, who had ex­tended a vol­un­tary non-ex­clu­sive li­cense to a hand­ful In­dian and Pak­istani com­pa­nies to man­u­fac­ture and mar­ket the drug.

“We have been deeply in­vested in ex­plor­ing all pos­si­ble av­enues to save mil­lions of lives im­pacted by COVID-19 pan­demic...”

Newspapers in English

Newspapers from Fiji

© PressReader. All rights reserved.